Semax: limits of adverse-reaction evidence
Filippenkov and colleagues studied ACTH(4–7)PGP (Semax) in a rat cerebral-ischaemia model. The 2020 abstract describes gene expression 24 hours after ischaemia modelling. [1]
This abstract gives no clinical adverse-reaction frequencies. Administration route has not been verified from it; these data cannot establish human or batch-specific safety for Semax. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Clinical adverse-reaction frequencies | Rat cerebral-ischaemia model; gene expression 24 hours after ischaemia modelling | The abstract gives no clinical adverse-reaction frequencies; these data cannot establish human safety for Semax | [1] |
References
- Filippenkov IB et al. (2020). Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats https://doi.org/10.3390/genes11060681.